HIV Research Today is a free monthly online journal that collates and summarizes the latest research about HIV, including details on human immunodeficiency virus, testing, treatment, prevention, vaccines, aids.

Volume 6 (2009), Issue 4 (April)

1. In vitro glutaminase regulation and mechanisms of glutamate generation in HIV-1-infected macrophage.
   J Neurochem, 109(2): 551-61. [Abstract] [Full-text]
2. Safety of Switching Nevirapine Twice Daily to Nevirapine Once Daily in Virologically Suppressed Patients.
   J Acquir Immune Defic Syndr, 50(4): 390-6. [Abstract] [Full-text]
3. Resistance to CCR5 inhibitors caused by sequence changes in the fusion peptide of HIV-1 gp41.
   Proc Natl Acad Sci U S A, 106(13): 5318-23. [Abstract] [Full-text]
4. Inhibition of human immunodeficiency virus type 1 (HIV-1) nuclear import via Vpr-Importin alpha interactions as a novel HIV-1 therapy.
   Biochem Biophys Res Commun, 380(4): 838-43. [Abstract] [Full-text]
5. Reactive lymphadenopathy in Ugandan patients and its relationship to EBV and HIV infection.
   APMIS, 117(4): 302-7. [Abstract] [Full-text]
6. Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and coxsackie B4 virus.
   J Med Chem, 52(7): 1922-34. [Abstract] [Full-text]
7. Suitability of simple human immunodeficiency virus rapid tests in clinical trials in community-based clinic settings.
   J Clin Microbiol, 47(4): 1058-62. [Abstract] [Full-text]
8. Nevirapine resistance in human immunodeficiency virus type 1-positive infants determined using dried blood spots stored for up to six years at room temperature.
   J Clin Microbiol, 47(4): 1209-11. [Abstract] [Full-text]
9. Correlation between human immunodeficiency virus type 1 (HIV-1) RNA measurements obtained with dried blood spots and those obtained with plasma by use of Nuclisens EasyQ HIV-1 and Abbott RealTime HIV load tests.
   J Clin Microbiol, 47(4): 1031-6. [Abstract] [Full-text]
10. Single-point mutations causing more than 100-fold underestimation of human immunodeficiency virus type 1 (HIV-1) load with the Cobas TaqMan HIV-1 real-time PCR assay.
    J Clin Microbiol, 47(4): 1238-40. [Abstract] [Full-text]
11. Comparison of the Abbott realtime human immunodeficiency virus type 1 (HIV-1) assay to the Cobas AmpliPrep/Cobas TaqMan HIV-1 test: workflow, reliability, and direct costs.
    J Clin Microbiol, 47(4): 889-95. [Abstract] [Full-text]
12. Evaluation of different RNA extraction methods and storage conditions of dried plasma or blood spots for human immunodeficiency virus type 1 RNA quantification and PCR amplification for drug resistance testing.
    J Clin Microbiol, 47(4): 1107-18. [Abstract] [Full-text]
13. Association of HIV-specific and total CD8+ T memory phenotypes in subtype C HIV-1 infection with viral set point.
    J Immunol, 182(8): 4751-61. [Abstract] [Full-text]
14. Seroprevalence of chronic hepatitis B virus infection among taiwanese human immunodeficiency virus type 1-positive persons in the era of nationwide hepatitis B vaccination.
    Am J Gastroenterol, 104(4): 877-84. [Abstract] [Full-text]
15. Identification of a particular HIV-specific CD8+ T-cell subset with a CD27+ CD45RO-/RA+ phenotype and memory characteristics after initiation of HAART during acute primary HIV infection.
    Blood, 113(14): 3209-17. [Abstract] [Full-text]
16. Fidelity of plus-strand priming requires the nucleic acid chaperone activity of HIV-1 nucleocapsid protein.
    Nucleic Acids Res, 37(6): 1755-66. [Abstract] [Full-text]
17. Assisted reproduction for couples affected by human immunodeficiency virus in California.
    Fertil Steril, 91(4): 1540-3. [Abstract] [Full-text]
18. Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy.
    Clin Infect Dis, 48(9): 1296-305. [Abstract] [Full-text]
19. Low levels of antiretroviral-resistant HIV infection in a routine clinic in Cameroon that uses the World Health Organization (WHO) public health approach to monitor antiretroviral treatment and adequacy with the WHO recommendation for second-line treatment.
    Clin Infect Dis, 48(9): 1318-22. [Abstract] [Full-text]
20. Is the interruption of antiretroviral treatment during pregnancy an additional major risk factor for mother-to-child transmission of HIV type 1?
    Clin Infect Dis, 48(9): 1310-7. [Abstract] [Full-text]
21. Is HIV becoming more virulent? Initial CD4 cell counts among HIV seroconverters during the course of the HIV epidemic: 1985-2007.
    Clin Infect Dis, 48(9): 1285-92. [Abstract] [Full-text]
22. Mechanism analysis indicates that recombination events in HIV-1 initiate and complete over short distances, explaining why recombination frequencies are similar in different sections of the genome.
    J Mol Biol, 388(1): 30-47. [Abstract] [Full-text]
23. Proinflammatory cytokines and HIV-1 synergistically enhance CXCL10 expression in human astrocytes.
    Glia, 57(7): 734-43. [Abstract] [Full-text]
24. Conformational stability and membrane interaction of the full-length ectodomain of HIV-1 gp41: implication for mode of action.
    Biochemistry, 48(14): 3166-75. [Abstract] [Full-text]
25. Stochastic modelling of genotypic drug-resistance for human immunodeficiency virus towards long-term combination therapy optimization.
    Bioinformatics, 25(8): 1040-7. [Abstract] [Full-text]
26. Drug-resistant molecular mechanism of CRF01_AE HIV-1 protease due to V82F mutation.
    J Comput Aided Mol Des, 23(5): 261-72. [Abstract] [Full-text]
27. Suppression of Tetherin-restricting activity upon human immunodeficiency virus type 1 particle release correlates with localization of Vpu in the trans-Golgi network.
    J Virol, 83(9): 4574-90. [Abstract] [Full-text]
28. HLA footprints on human immunodeficiency virus type 1 are associated with interclade polymorphisms and intraclade phylogenetic clustering.
    J Virol, 83(9): 4605-15. [Abstract] [Full-text]
29. Replicative capacity differences of thymidine analog resistance mutations in subtype B and C human immunodeficiency virus type 1.
    J Virol, 83(9): 4051-9. [Abstract] [Full-text]
30. Preclinical studies of human immunodeficiency virus/AIDS vaccines: inverse correlation between avidity of anti-Env antibodies and peak postchallenge viremia.
    J Virol, 83(9): 4102-11. [Abstract] [Full-text]
31. The F12-Vif derivative Chim3 inhibits HIV-1 replication in CD4+ T lymphocytes and CD34+-derived macrophages by blocking HIV-1 DNA integration.
    Blood, 113(15): 3443-52. [Abstract] [Full-text]
32. Human immunodeficiency virus integrates directly into naive resting CD4+ T cells but enters naive cells less efficiently than memory cells.
    J Virol, 83(9): 4528-37. [Abstract] [Full-text]
33. Intercellular adhesion molecule 1 (ICAM-1), but not ICAM-2 and -3, is important for dendritic cell-mediated human immunodeficiency virus type 1 transmission.
    J Virol, 83(9): 4195-204. [Abstract] [Full-text]
34. Identification of a human immunodeficiency virus type 1 envelope glycoprotein variant resistant to cold inactivation.
    J Virol, 83(9): 4476-88. [Abstract] [Full-text]
35. Major coexisting human immunodeficiency virus type 1 env gene subpopulations in the peripheral blood are produced by cells with similar turnover rates and show little evidence of genetic compartmentalization.
    J Virol, 83(9): 4068-80. [Abstract] [Full-text]
36. JC virus-specific immune responses in human immunodeficiency virus type 1 patients with progressive multifocal leukoencephalopathy.
    J Virol, 83(9): 4404-11. [Abstract] [Full-text]
37. Noncytotoxic suppression of human immunodeficiency virus type 1 transcription by exosomes secreted from CD8+ T cells.
    J Virol, 83(9): 4354-64. [Abstract] [Full-text]
38. Requirement for microtubule integrity in the SOCS1-mediated intracellular dynamics of HIV-1 Gag.
    FEBS Lett, 583(8): 1243-50. [Abstract] [Full-text]
39. Increased detection of proliferating, polyfunctional, HIV-1-specific T cells in DNA-modified vaccinia virus Ankara-vaccinated human volunteers by cultured IFN-gamma ELISPOT assay.
    Eur J Immunol, 39(4): 975-85. [Abstract] [Full-text]
40. A method for identification of HIV gp140 binding memory B cells in human blood.
    J Immunol Methods, 343(2): 65-7. [Abstract] [Full-text]
41. HIV Gag p24 specific responses secreting IFN-gamma and/or IL-2 in treatment-naïve individuals in acute infection early disease (AIED) are associated with low viral load.
    Clin Immunol, 131(2): 277-87. [Abstract] [Full-text]
42. Production of the p24 capsid protein from HIV-1 subtype C in Arabidopsis thaliana and Daucus carota using an endoplasmic reticulum-directing SEKDEL sequence in protein expression constructs.
    Protein Expr Purif, 66(1): 46-51. [Abstract] [Full-text]
43. Mimicking the structure of the V3 epitope bound to HIV-1 neutralizing antibodies.
    Biochemistry, 48(15): 3288-303. [Abstract] [Full-text]
44. Sifuvirtide, a potent HIV fusion inhibitor peptide.
    Biochem Biophys Res Commun, 382(3): 540-4. [Abstract] [Full-text]
45. Isolation of a cellular factor that can reactivate latent HIV-1 without T cell activation.
    Proc Natl Acad Sci U S A, 106(15): 6321-6. [Abstract] [Full-text]
46. Scaleable manufacture of HIV-1 entry inhibitor griffithsin and validation of its safety and efficacy as a topical microbicide component.
    Proc Natl Acad Sci U S A, 106(15): 6099-104. [Abstract] [Full-text]
47. Effect of highly active antiretroviral therapy on incident AIDS using calendar period as an instrumental variable.
    Am J Epidemiol, 169(9): 1124-32. [Abstract] [Full-text]
48. Decreased respiratory quotient in relation to resting energy expenditure in HIV-infected and noninfected subjects.
    Metabolism, 58(5): 608-15. [Abstract] [Full-text]
49. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies.
    Lancet, 373(9672): 1352-63. [Abstract] [Full-text]
50. Mutations in gp120 contribute to the resistance of human immunodeficiency virus type 1 to membrane-anchored C-peptide maC46.
    J Virol, 83(10): 4844-53. [Abstract] [Full-text]
51. Impact of human immunodeficiency virus type 1 resistance to protease inhibitors on evolution of resistance to the maturation inhibitor bevirimat (PA-457).
    J Virol, 83(10): 4884-94. [Abstract] [Full-text]
52. Broad neutralization of human immunodeficiency virus type 1 (HIV-1) elicited from human rhinoviruses that display the HIV-1 gp41 ELDKWA epitope.
    J Virol, 83(10): 5087-100. [Abstract] [Full-text]
53. Selection of a simian-human immunodeficiency virus strain resistant to a vaginal microbicide in macaques.
    J Virol, 83(10): 5067-76. [Abstract] [Full-text]
54. A limited group of class I histone deacetylases acts to repress human immunodeficiency virus type 1 expression.
    J Virol, 83(10): 4749-56. [Abstract] [Full-text]
55. The human immunodeficiency virus type 2 Vpx protein usurps the CUL4A-DDB1 DCAF1 ubiquitin ligase to overcome a postentry block in macrophage infection.
    J Virol, 83(10): 4854-60. [Abstract] [Full-text]
56. Role of natural killer cells in a cohort of elite suppressors: low frequency of the protective KIR3DS1 allele and limited inhibition of human immunodeficiency virus type 1 replication in vitro.
    J Virol, 83(10): 5028-34. [Abstract] [Full-text]
57. Single-molecule immunosorbent assay as a tool for human immunodeficiency virus-1 antigen detection.
    Anal Bioanal Chem, 394(2): 489-97. [Abstract] [Full-text]
58. Elucidating the inhibition mechanism of HIV-1 non-nucleoside reverse transcriptase inhibitors through multicopy molecular dynamics simulations.
    J Mol Biol, 388(3): 644-58. [Abstract] [Full-text]
59. HIV-1 reverse transcriptase can simultaneously engage its DNA/RNA substrate at both DNA polymerase and RNase H active sites: implications for RNase H inhibition.
    J Mol Biol, 388(3): 462-74. [Abstract] [Full-text]
60. Mucosal immune responses to HIV-1 in elite controllers: a potential correlate of immune control.
    Blood, 113(17): 3978-89. [Abstract] [Full-text]
61. Genetically modified CD34+ hematopoietic stem cells contribute to turnover of brain perivascular macrophages in long-term repopulated primates.
    Am J Pathol, 174(5): 1808-17. [Abstract] [Full-text]
62. Sequence-specific detection method for reverse transcription, loop-mediated isothermal amplification of HIV-1.
    J Med Virol, 81(6): 966-72. [Abstract] [Full-text]
63. Absence of genotypic drug resistance and presence of several naturally occurring polymorphisms of human immunodeficiency virus-1 CRF06_cpx in treatment-naive patients in Estonia.
    J Med Virol, 81(6): 953-8. [Abstract] [Full-text]
64. HIV-1 matrix organizes as a hexamer of trimers on membranes containing phosphatidylinositol-(4,5)-bisphosphate.
    Virology, 387(2): 466-72. [Abstract] [Full-text]
65. Restriction of HIV-1 by APOBEC3G is cytidine deaminase-dependent.
    Virology, 387(2): 313-21. [Abstract] [Full-text]
66. Inefficient entry of vicriviroc-resistant HIV-1 via the inhibitor-CCR5 complex at low cell surface CCR5 densities.
    Virology, 387(2): 296-302. [Abstract] [Full-text]
67. Maternal neutralizing antibodies against a CRF01_AE primary isolate are associated with a low rate of intrapartum HIV-1 transmission.
    Virology, 387(2): 388-94. [Abstract] [Full-text]
68. High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination.
    Virology, 387(2): 414-26. [Abstract] [Full-text]
69. Control of viremia and maintenance of intestinal CD4(+) memory T cells in SHIV(162P3) infected macaques after pathogenic SIV(MAC251) challenge.
    Virology, 387(2): 273-84. [Abstract] [Full-text]
70. Characterization of a myristoylated, monomeric HIV Gag protein.
    Virology, 387(2): 341-52. [Abstract] [Full-text]
71. Centrifugation improves the detection of HIV-1 p24 antigen in plasma from children born to mothers infected with HIV-1.
    J Virol Methods, 158(1): 6-10. [Abstract] [Full-text]
72. Investigation of requirements for efficient gene delivery using the HIV-1 based lentiviral transduction system.
    Biochem Biophys Res Commun, 383(2): 192-7. [Abstract] [Full-text]
73. Antiretroviral activity of fucoidans extracted from the brown seaweed Adenocystis utricularis.
    Phytother Res, 23(5): 707-12. [Abstract] [Full-text]
74. HIV and SIV infection: the role of cellular restriction and immune responses in viral replication and pathogenesis.
    APMIS, 117(5): 400-12. [Abstract] [Full-text]
75. Dried-plasma transport using a novel matrix and collection system for human immunodeficiency virus and hepatitis C virus virologic testing.
    J Clin Microbiol, 47(5): 1491-6. [Abstract] [Full-text]
76. Impact of discrepancies between the Abbott realtime and cobas TaqMan assays for quantification of human immunodeficiency virus type 1 group M non-B subtypes.
    J Clin Microbiol, 47(5): 1543-5. [Abstract] [Full-text]

© 2004-2010 HIV Research Today. All Rights Reserved.